The aim of this study was to determine whether parameters related to TBI impacted upon OS and relapse in patients with acute leukemia in CR who underwent haematopoietic SCT (HSCT) in 11 Italian Radiation Oncology Centres. Data were analysed from 507 patients (313 males; 194 females; median age 15 years; 318 with ALL; 188 with AML; 1 case not recorded). Besides 128 autologous transplants, donors included 192 matched siblings, 74 mismatched family members and 113 unrelated individuals. Autologous and allogeneic transplants were analysed separately. Median follow-up was 40.1 months. TBI schedules and HSCT type were closely related. Uni- and multi-variate analyses showed no parameter was significant for OS or relapse in autologous transplantation. Multivariate analysis showed type of transplant and disease impacted significantly on OS in allogeneic transplantation. Disease, GVHD and TBI dose were risk factors for relapse. This analysis illustrates that Italian Transplant Centre use of TBI is in line with international practice. Most Centres adopted a hyperfractionated schedule that is used worldwide (12 Gy in six fractions over 3 days), which appears to have become standard. TBI doses impacted significantly upon relapse rates.
In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study / C Aristei;A Santucci;R Corvò;G Gardani;U Ricardi;G Scarzello;S M Magrini;V Donato;L Falcinelli;A Bacigalupo;F Locatelli;F Aversa;E Barbieri;Cynthia Aristei;Lorenzo Falcinelli;Gianni Gobbi;Carlo Raymondi;Franco Aversa;Antonella Santucci;Enza Barbieri;Andrea Ferri;Giuseppe Bandini;Andrea Pession;Stefano Maria Magrini;Filippo Bertoni;Marco Galelli;Sandro Tonoli;Michela Buglione di Monale e Bastia;Renzo Corvò;Franca Foppiano;Salvina Barra;Andrea Bacigalupo;Francesco Frassoni;Barbara Bruno;Giorgio Dini;Maura Faraci;Gianstefano Gardani;Cornelio Uderzo;Andrea Crespi;Giovanni Scarzello;Roberto Zandonà;Chiara Messina;Vittorio Donato;Lavinia Grapulin;Cinzia Di Felice;Elisabetta Di Castro;Anna Paola Iori;Walter Barbieri;William Arcese;Michele Troiano;Salvatore Parisi;Alberto Maiorana;Angelo Michele Carella;Umberto Ricardi;Giuseppe Rossi;Andrea Riccardo Filippi;Riccardo Ragona;Luigi Tomio;Rosa Bianca Guglielmi;Cristina Baiocchi;Paolo Scalchi;Roberto Raimondi;Cristiana Vidali S.C.;Natasha Maximova. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - STAMPA. - 48:7(2013), pp. 908-914. [10.1038/bmt.2013.66]
In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study
PESSION, ANDREA;
2013
Abstract
The aim of this study was to determine whether parameters related to TBI impacted upon OS and relapse in patients with acute leukemia in CR who underwent haematopoietic SCT (HSCT) in 11 Italian Radiation Oncology Centres. Data were analysed from 507 patients (313 males; 194 females; median age 15 years; 318 with ALL; 188 with AML; 1 case not recorded). Besides 128 autologous transplants, donors included 192 matched siblings, 74 mismatched family members and 113 unrelated individuals. Autologous and allogeneic transplants were analysed separately. Median follow-up was 40.1 months. TBI schedules and HSCT type were closely related. Uni- and multi-variate analyses showed no parameter was significant for OS or relapse in autologous transplantation. Multivariate analysis showed type of transplant and disease impacted significantly on OS in allogeneic transplantation. Disease, GVHD and TBI dose were risk factors for relapse. This analysis illustrates that Italian Transplant Centre use of TBI is in line with international practice. Most Centres adopted a hyperfractionated schedule that is used worldwide (12 Gy in six fractions over 3 days), which appears to have become standard. TBI doses impacted significantly upon relapse rates.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
